Emerging Options for the Prevention and Management of Clostridioides difficile Infection

Anne J Gonzales-Luna1, Travis J Carlson2, Kevin W Garey3

  • 1Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 4849 Calhoun Road, Houston, TX, 77204, USA.

Drugs
|January 16, 2023
PubMed

Insights

New Clostridioides difficile infection treatments in late-stage trials include antibiotics, microbiome restoration, and vaccines. This review covers agents in Phase III trials for effective clinical adoption.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Vaccinology

Background:

  • Clostridioides difficile infection (CDI) poses a significant clinical challenge.
  • Existing treatments have limitations, driving the need for novel strategies.
  • A diverse range of therapeutic approaches are under investigation for CDI.

Approach:

  • This narrative review focuses on agents in late-stage clinical development (Phase III).
  • Key agents examined include one antibiotic, three live biotherapeutic products (LBPs), and two toxoid vaccines.
  • Information was gathered from registered clinical trials on ClinicalTrials.gov.

Key Points:

  • Ridinilazole is a novel antibiotic targeting CDI.
  • CP101, RBX2660, and SER109 represent LBPs for microbiome restoration.
  • PF06425090 and another toxoid vaccine are in late-stage development for CDI prevention/treatment.

Conclusions:

  • Several promising agents are progressing through Phase III trials for CDI.
  • Understanding these late-stage candidates is crucial for clinical decision-making.
  • The review provides insights into emerging CDI prevention and treatment strategies.

Related Concept Videos

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.7K
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
3.9K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
385
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
260
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
186